Bayer's Rapeseed Biofuel Pivot Meets a Pharma Pipeline Finally Pulling Its Weight - ad-hoc-news.de
Article excerpt
Highlighted: the sentence this signal was extracted from
Bayer spent this week doing what it has done for much of the year: stacking up catalysts across two very different businesses. On Wednesday the Leverkusen group unveiled a commercial agreement with Finnish refiner Neste to scale its newgold® winter rapeseed for biofuel production, a move that slots agriculture squarely into the energy transition. A day earlier, Barclays had raised its price target on the stock from EUR 60 to EUR 70 while keeping an Overweight rating - the most bullish call among major houses, with J.P. Morgan at EUR 61 and UBS at EUR 62. The market's response was muted. Bayer shares changed hands at EUR 47.87 on Friday, down 1.3% on the day and 2.0% over the week, leaving the stock below its 50-day average of EUR 48.56. Zoom out, though, and the picture shifts: the equity is up 29% year-to-date and 66% over twelve months, and it still sits comfortably above its 200-day line of EUR 42.13 - roughly 15% higher, and about 9.7% shy of the 52-week peak of EUR 53.86. The Neste tie-up targets a niche Bayer increasingly treats as strategic: agricultural raw materials destined not for plates but for renewable energy feedstocks. Under the arrangement, newgold® winter rapeseed is meant to strengthen biofuel supply chains, with Neste acting as the buyer and processor. It is the latest in a string of Crop Science announcements, following recent progress updates on...
Keep reading with a free account
The rest of this article, and every signal for Bayer, is in your free account.
